All In Biotech

Free tool

FAERS Monitor: Tissueblue

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209569 or its brand name (Tissueblue, Brilliant Blue G). Reports on generic versions are filed under their own applications.

Reports

21

Serious

16

76% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disability3
  • visual impairment3
  • blindness2
  • non-infectious endophthalmitis2
  • toxic anterior segment syndrome2
  • adverse drug reaction1
  • drug hypersensitivity1
  • endophthalmitis1
  • eye disorder1
  • eye injury1
  • hemianopia1
  • impaired quality of life1
  • injection site discolouration1
  • iris adhesions1
  • macular hole1

Reports by year received

View as table
YearReports
20181
20203
20214
20225
20233
20242
20252
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
non-infectious endophthalmitis22367.4632.42,654
iris adhesions11958.2288.6488
toxic anterior segment syndrome21841.3492.12,065
hemianopia11011.7149.2252
macular hole1747.1110.2186
eye injury1329.848.781
endophthalmitis1167.024.741
disabilitySignal3152.053.3312
injection site discolouration180.211.819
impaired quality of life169.710.316
blindness249.213.252
eye disorder130.54.57
visual impairmentSignal324.28.546
adverse drug reaction111.21.62
drug hypersensitivity15.20.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.